Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin in Recurrent or Refractory Osteosarcoma
NCT02097238Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Aug 2014
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of eribulin in osteosarcoma (OS), sponsored by National Cancer Institute. Primary endpoints: Disease Control Success at 4 months and Objective Response Rate at 4 months. Started Aug 2014; status: completed.
02
Drugs
eribulin
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NCT02097238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02097238.